Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
502-04-008 ISMRM Abstract

Association of background parenchymal enhancement suppression during neoadjuvant chemotherapy with breast cancer survival

Primary: Body - Breast
Secondary: Analysis Methods - Classification and Prediction
502-04-008 · New Developments in Breast MRI · Wednesday, 13 May, 4:00 PM–5:50 PM · Hall 1B
Keywords: Breast cancer Background parenchymal enhancement Breast MRI Neoadjuvant Chemotherapy Survival analysis
Accepted
Natsuko Onishi , Wen Li1, Matthew Gibbons1, Lisa Wilmes1, Pouya Metanat1, Teffany Joy Bareng1, Bonnie Joe1, John Kornak2, Christina Yau3, I-SPY 2 Investigator Network, I-SPY2 Imaging Working Group, Laura J Esserman3, Nola Hylton4
1Department of Radiology and Biomedical Imaging, University Of California, San Francisco (UCSF), United States of America
2Department of Epidemiology & Biostatistics, University Of California, San Francisco (UCSF), United States of America
3Department of Surgery, University Of California, San Francisco (UCSF), United States of America
4University Of California, San Francisco (UCSF), United States of America
Presenting Author: Natsuko Onishi

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Müller-Schimpfle M, Ohmenhaüser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203: 145–9. 10.1148/radiology.203.1.9122383 [doi]
2. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203: 137–44. 10.1148/radiology.203.1.9122382 [doi]
3. Nissan N, Bauer E, Moss Massasa EE, Sklair-Levy M. Breast MRI during pregnancy and lactation: clinical challenges and technical advances. Insights Imaging 2022; 13: 71. 10.1186/s13244-022-01214-7 [doi]
4. Okuma H, Masarwah A, Istomin A, et al. Increased background parenchymal enhancement on peri-menopausal breast magnetic resonance imaging. Eur J Radiol Open 2024; 13: 100611. 10.1016/j.ejro.2024.100611 [doi]
5. King V, Goldfarb SB, Brooks JD, et al. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. Radiology 2012; 264: 670–8. 10.1148/radiol.12112669 [doi]
6. Schrading S, Schild H, Kühr M, Kuhl C. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study. Radiology 2014; 271: 45–55. 10.1148/radiol.13131198 [doi]
7. Schrading S, Kuhl CK. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging. Radiology 2015; 277: 687–96. 10.1148/radiol.2015150006 [doi]
8. Onishi N, Li W, Newitt DC, et al. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology 2021; 301: 295–308. 10.1148/radiol.2021203645 [doi]
9. Preibsch H, Wanner L, Bahrs SD, et al. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol 2016; 26: 1590–6. 10.1007/s00330-015-4011-x [doi]
10. Chen JH, Yu HJ, Hsu C, Mehta RS, Carpenter PM, Su MY. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Transl Oncol 2015; 8: 204–9. 10.1016/j.tranon.2015.04.001 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/502-04-008